Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print October 1, 2007
DOI: 10.2337/db07-0733

This Article
Right arrow Full Text (PDF)
Right arrow Online-Only Appendix
Right arrow All Versions of this Article:
db07-0733v1
57/1/86    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tolle, V.
Right arrow Articles by Low, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tolle, V.
Right arrow Articles by Low, M. J.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

In vivo evidence for inverse agonism of agouti related peptide in the central nervous system of proopiomelanocortin deficient mice

Virginie Tolle, PhD1,,2, and Malcolm J. Low, MD, PhD1,,2,,3

1Center for the Study of Weight Regulation and Associated Disorders,
2Vollum Institute,
3Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon, USA

OBJECTIVE: Melanocyte stimulating hormone (MSH) peptides processed from proopiomelanocortin (POMC) regulate energy homeostasis by activating neuronal melanocortin receptor (MC-R) signaling. Agouti related peptide (AgRP) is a naturally occurring MC-R antagonist, but also displays inverse agonism at constitutively active MC4-R expressed on transfected cells. We investigated whether AgRP functions similarly in vivo using mouse models that lack all neuronal MSH, thereby precluding competitive antagonism of MC-R by AgRP.

RESEARCH DESIGN AND METHODS: Feeding and metabolic effects of the MC-R agonist MTII, AgRP, and ghrelin were investigated after icv injection in neural-specific POMC-deficient (Pomc–/–Tg/+) and global POMC-deficient (Pomc–/–) mice. Gene expression was quantified by RT-PCR.

RESULTS: Hyperphagic POMC-deficient mice were more sensitive than wildtype mice to the anorectic effects of MTII. Hypothalamic MC3/4-R mRNAs in POMC-deficient mice were unchanged, suggesting increased receptor sensitivity as a possible mechanism for the heightened anorexia. AgRP reversed MTII-induced anorexia in both mutant strains, demonstrating its ability to antagonize MSH agonists at central MC3/4-R, but did not produce an acute orexigenic response by itself. Ghrelin's action was attenuated in Pomc–/–Tg/+ mice, suggesting decreased sensitivity to additional orexigenic signals. However, AgRP induced delayed and long-lasting modifications of energy balance in Pomc–/–Tg/+, but not glucocorticoid-deficient Pomc–/– mice, by decreasing oxygen consumption, increasing the respiratory exchange ratio, and increasing food intake.

CONCLUSIONS: These data demonstrate that AgRP can modulate energy balance via a mechanism independent of MSH and MC3/4-R competitive antagonism, consistent with either inverse agonist activity at MC-R or interaction with a distinct receptor.


Correspondence: virginie.tolle{at}broca.inserm.fr

Key Words: Agouti Related Peptide (AgRP) • Proopiomelanocortin (POMC) • melanocortin receptors (MC-R) • melanotan II (MTII) • inverse agonism • food intake • indirect calorimetry


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.